AndroGel® is the first-ever testosterone replacement gel to be approved by the FDA for replacement therapy in men for conditions associated with low testosterone. Low testosterone, also known as hypogonadism, affects approximately four to five million American men. The condition is linked with diminished interest in sex, impotence, reduced lean body mass, decreased bone density and lowered mood and energy levels. AndroGel® will be available with a prescription in pharmacies throughout the United States by mid-summer 2000 by Unimed Pharmaceuticals.

The unique method of transport (rub in gel) offers many benefits. Those traumatized by needles will surely enjoy rubbing in testosterone to the skin, apposed to injecting it intra-muscularly. Although the therapeutic dose may fall short of being anabolic enough for some.

Testosterone is the chemical name of active ingredient in AndroGel and Androderm. AndroGel is a registered trademark of Unimed Pharmaceuticals. Androderm is a registered trademark of Watson Pharmaceuticals, Inc.

Transdermal Testosterone Resources

Androgel Pictures
AndroGel Package Insert
Androderm Package Insert

Trivial name	Testosterone [USAN:INN] (base)
Chemical name	17ß-hydroxyandrost-4-en-3-one
Systematic Name	(8S,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
Index name	Androst-4-en-17beta-ol-3-one
CAS number	58-22-0
Empirical formula	C19-H28-O2
Merck Index Number	Merck 11, 9109
Molecular weight	288.424 g/mol
Pregnancy category	X
Legal status	Prescription only (US); DEA Schedule III (US)
Routes of administration	Transdermal

Visit Our Forums to Learn More About Anabolic Steroids